Suppr超能文献

斑秃与注意缺陷/多动障碍兴奋剂药物的关联:一项病例对照研究。

Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study.

作者信息

Meaux Tyson A, McMahon Pamela M, Jones Glenn N, Bush Amelia E, Kennedy Jaren J, Poche George William

机构信息

Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans, LA.

Pediatric Residency Program, Our Lady of the Lake Children's Hospital, Baton Rouge, LA.

出版信息

Ochsner J. 2021 Summer;21(2):139-142. doi: 10.31486/toj.20.0025.

Abstract

Both psychiatric disorders and diverse medications used to treat them have been associated with alopecia. The objective of our study was to investigate the existence of an association between attention-deficit/hyperactivity disorder (ADHD) stimulant medication (ASM) and various types of alopecia. We conducted a retrospective case-control medical record review of patients between the ages of 6 and 18 years seen in dermatology clinics during a 10-year period. Cases included patients diagnosed with alopecia areata (AA), alopecia totalis (AT), or alopecia universalis (AU). We matched 3 controls on age and sex to each case. We reviewed patients' medical records for the following medications: lisdexamfetamine, amphetamine/dextroamphetamine, dexmethylphenidate, and methylphenidate. We examined the association between medications used to treat ADHD and diagnoses of AA, AT, and/or AU by calculating a series of odds ratios and 95% CIs. We identified 124 cases (110 with AA, 11 with AT, and 3 with AU) and 372 controls. We found a strong association between AU and ASM use (<0.0071). No relationship between ASM use and other types of hair loss was found. Although the sample size of cases with AU was small, we found a significant association between AU and ASM. While further study is needed, practitioners may consider close monitoring of patients with AA who use ASM for the development of worsening disease and discontinue the medication if the patient experiences an increase in hair loss that appears to be progressing to AU.

摘要

精神疾病及其用于治疗的各种药物都与脱发有关。我们研究的目的是调查注意力缺陷多动障碍(ADHD)兴奋剂药物(ASM)与各种类型脱发之间是否存在关联。我们对10年间皮肤科诊所6至18岁的患者进行了一项回顾性病例对照病历审查。病例包括被诊断为斑秃(AA)、全秃(AT)或普秃(AU)的患者。我们为每个病例匹配3名年龄和性别相匹配的对照。我们查阅了患者病历中以下药物的使用情况:赖右苯丙胺、苯丙胺/右旋苯丙胺、右美沙芬酯和哌甲酯。我们通过计算一系列比值比和95%置信区间,研究了用于治疗ADHD的药物与AA、AT和/或AU诊断之间的关联。我们确定了124例病例(110例AA、11例AT和3例AU)和372名对照。我们发现AU与使用ASM之间存在强关联(<0.0071)。未发现使用ASM与其他类型脱发之间存在关联。尽管AU病例的样本量较小,但我们发现AU与ASM之间存在显著关联。虽然还需要进一步研究,但从业者可能会考虑密切监测使用ASM的AA患者是否出现病情恶化,如果患者出现脱发增加且似乎进展为AU,则停用该药物。

相似文献

8
10
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.美国青少年斑秃患者的医疗服务利用情况及费用
J Health Econ Outcomes Res. 2022 Jul 29;9(2):11-18. doi: 10.36469/001c.36229. eCollection 2022.

本文引用的文献

1
Telogen effluvium: a comprehensive review.休止期脱发:全面综述
Clin Cosmet Investig Dermatol. 2019 Aug 21;12:583-590. doi: 10.2147/CCID.S200471. eCollection 2019.
4
Telogen Effluvium: Is There a Need for a New Classification?休止期脱发:是否需要新的分类?
Skin Appendage Disord. 2016 Sep;2(1-2):39-44. doi: 10.1159/000446119. Epub 2016 May 21.
6
Alopecia universalis successfully treated with adalimumab.全身性斑秃用阿达木单抗成功治疗。
JAMA Dermatol. 2014 Dec;150(12):1341-4. doi: 10.1001/jamadermatol.2014.1544.
7
Anagen effluvium.生长期脱发。
Indian J Dermatol Venereol Leprol. 2013 Sep-Oct;79(5):604-12. doi: 10.4103/0378-6323.116728.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验